China’s biotech surge upends the global CDMO model

This transformation is evident in the pipeline. In 2025 Asia reached a 43% share of the global innovative pipeline, largely driven by China’s 30% contribution. Discovery-to-clinical-trial cycles are 50–70% faster than the global average, and trials run 2–5 times quicker than in the US and EU thanks to denser patient pools, streamlined review and experienced investigators. 

Analysts identify China as a global leader in ADCs and multispecific antibodies, rapidly expanding in protein degraders, RNA therapies and radioligands, often second only to the US. Vision Lifesciences, which has offices in Hong Kong, China, Europe and the US, reports that China accounts for nearly 90% of global ADC licensing activity. 

External investors reinforce this narrative. PitchBook analyst Ben Zercher notes that China has ‘gained the lead’ in generating early-stage drug candidates, and that this advantage is likely to persist for several years. Venture capital is increasingly flowing into complex modalities such as nucleic acid therapies and cell and gene therapies: by 2025, nearly half of Chinese biotech venture deals involved these advanced assets, highlighting capital’s focus on frontier science rather than incremental innovation. 

For Western R&D chiefs, the pressing question is no longer whether Chinese innovation matters, but how to access it without ceding strategic control over data, manufacturing and geopolitical exposure.

On the supply side, Chinese contract development and manufacturing organisations (CDMOs) have evolved from low-cost bulk suppliers into deeply integrated partners. Grand View Research estimates that the Chinese pharmaceutical CDMO market generated $18.9 billion in 2024, and projects it to reach $39.5 billion by 2033 (a CAGR of 8.6%). 

Chinese players such as WuXi STA (Shanghai) and Pharmaron (Beijing) now feature alongside incumbents such as Lonza (Basel) and Catalent (Somerset, New Jersey) on sponsor shortlists. At Interphex 2026, panellists described China’s contract research organization (CRO) and CDMO infrastructure as ‘of staggering scale and sophistication – one that now rivals, and in many cases surpasses, its Western counterparts.’ 

These organisations bundle process development, the chemistry, manufacturing and controls (CMC) function, regulatory support, tech transfer and high-potency biologics manufacturing, often at speeds unmatched by Western networks. As oncology licensing increasingly hinges on complex ADCs and bispecifics, Chinese CDMOs are negotiating on price, geography, data flows and follow-on work.

Three converging trends – China’s innovation surge, the rising influence of its CDMOs and geopolitical tensions – pose a challenge beyond traditional procurement. Under pressure from patent cliffs and cost constraints, major pharma companies are increasingly reliant on Chinese assets for global dealmaking. These arrangements channel CMC and production work towards Chinese or China-linked CDMOs through partnerships or integrated models. 

Discussions at INTERPHEX 2026 indicated a shift from transactional outsourcing towards partnership-driven network design, prioritising capacity and resilience. Multinationals are adopting dual-sourcing strategies, pairing Asia-based supply routes for speed and cost efficiency with Western capacity for politically sensitive markets: a ‘belt and braces’ approach that balances access to innovation with geopolitical risk. 

This risk is intensifying. The US Biosecure Act of 18 December 2025 restricts federal procurement and grants involving “biotechnology companies of concern”, including certain CDMOs. Think tanks such as the Foundation for Defense of Democracies (for example, its analysis of pharmaceutical supplychain vulnerabilities and policy responses) and the Center for Strategic and International Studies warn that heavy reliance on Chinese active pharmaceutical ingredients (APIs) and biologics may create strategic vulnerabilities, prompting calls for reshoring, diversification and tighter regulatory oversight. 

Regulatory scrutiny is rising. Reduced foreign good manufacturing practice (GMP) inspections have led to more unannounced visits, increasing political exposure. European measures – including the Critical Medicines Alliance (2024) and the proposed Critical Medicines Act (2025) – aim to enhance supply chain resilience through stockpiling, joint procurement and investment in local manufacturing.

At Interphex 2026, panellists will debate the question: ‘Will China’s surge in biotech innovation upend global CDMO demand?’ One scenario envisions radical decoupling, in which the US and select allies restrict collaboration, data flows and manufacturing contracts with China, steering Chinese innovators towards regional and emerging markets while Western pharma consolidates around domestic or ‘friend-shored’ CDMOs.  

A more plausible near-term path is managed interdependence, in which China continues to command around one-third of global licensing spend and a quarter of licensed assets, while sponsors strategically segment which assets, data and manufacturing reside in Chinese or China-linked networks versus Organisation for Economic Co-operation and Development (OECD) jurisdictions. Success increasingly depends on digital sophistication: CDMOs demonstrating robust, auditable infrastructure, explainable artificial intelligence, knowledge-graph ‘twins’ and FAIR (Findable, Accessible, Interoperable, and Reusable) digital assets under compliant legal regimes gain preference for sensitive work. 

The era of naive globalisation – outsourcing solely to the lowest-cost facility – is coming to an end. Strategic manufacturing is now interwoven with data governance and geopolitical awareness. The winners will not be the cheapest CDMOs or the pharma companies with the largest in-house factories, but those that manage China as both an indispensable innovation engine and a structural risk, demonstrating transparency, digital maturity and compliance in an increasingly fragmented global ecosystem.

China’s innovation and rise as a leading CDMO hub has created a new fault line in global biopharma: geography is no longer the only differentiator – data, digital maturity and compliance are decisive. Organisations that treat manufacturing, licensing and data stewardship as interconnected strategic capabilities are gaining a competitive advantage. ADCs and other high-complexity modalities illustrate how innovation leadership directly translates into negotiating leverage, shaping supply chain design, regulatory strategy and partnership decisions. 

In a world of managed interdependence, the ultimate winners will be those who combine scientific capability with digital sophistication and geopolitical foresight, demonstrating that strategic balance is as crucial as scientific innovation.